Biomea Fusion, Inc. (BMEA)
| Market Cap | 97.60M +28.0% |
| Revenue (ttm) | n/a |
| Net Income | -44.95M |
| EPS | -0.74 |
| Shares Out | 72.30M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,913,877 |
| Open | 1.420 |
| Previous Close | 1.430 |
| Day's Range | 1.320 - 1.449 |
| 52-Week Range | 0.872 - 3.080 |
| Beta | -0.34 |
| Analysts | Buy |
| Price Target | 7.29 (+440.0%) |
| Earnings Date | May 11, 2026 |
About BMEA
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It’s lead clinical program’s drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for BMEA stock is "Buy." The 12-month stock price target is $7.29, which is an increase of 440.00% from the latest price.
News
Biomea Fusion to Participate at Upcoming Investor Conferences
SAN CARLOS, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that management wi...
Biomea Fusion reports Q1 EPS (17c), consensus (19c)
As of March 31, the company had cash, cash equivalents and restricted cash of $45.1M vs. $56.2M at previous quarter end. “Across our portfolio, we continue to execute with focus…
Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights
SAN CARLOS, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today reported it...
Biomea Fusion options imply 18.9% move in share price post-earnings
Pre-earnings options volume in Biomea Fusion (BMEA) is normal with calls leading puts 5:1. Implied volatility suggests the market is anticipating a move near 18.9%, or 0c, after results are…
Biomea Fusion options imply 23.1% move in share price post-earnings
Pre-earnings options volume in Biomea Fusion (BMEA) is normal with calls leading puts 211:1. Implied volatility suggests the market is anticipating a move near 23.1%, or 0c, after results are…
Biomea Fusion Announces Poster Presentations of Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions
SAN CARLOS, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced t...
Biomea Fusion Transcript: Status update
Icovamenib, a novel menin inhibitor, shows promise for both type 1 and type 2 diabetes by regenerating beta cells and offering durable glycemic control after short-term therapy. Early data indicate meaningful A1C and C-peptide improvements with a favorable safety profile.
Biomea Fusion initiated with an Outperform at Citizens
Citizens initiated coverage of Biomea Fusion (BMEA) with an Outperform rating and $9 price target The company is developing icovamenib, a covalent small-molecule menin inhibitor, which has shown the a...
Biomea Fusion options imply 22.0% move in share price post-earnings
Pre-earnings options volume in Biomea Fusion (BMEA) is normal with calls leading puts 4:1. Implied volatility suggests the market is anticipating a move near 22.0%, or 0c, after results are…
Biomea Fusion Transcript: Study result
Top-line results from the COVALENT-112 trial show that icovamenib led to a 52% increase in C-peptide at 12 weeks and sustained beta cell function at 52 weeks in recent-onset type 1 diabetes, with a favorable safety profile. A phase II study will further evaluate extended dosing and combination strategies.
Biomea Fusion announces positive 52-week results from phase 2 COVALENT-112 trial
Biomea Fusion (BMEA) “announced positive 52-week results from its Phase 2 COVALENT-112 trial evaluating the efficacy, safety, and tolerability of icovamenib in patients with type 1 diabetes. These dat...
Biomea Fusion Announces Positive 52-Week Results from Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib Treatment
SAN CARLOS, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced...
Biomea Fusion doses first patient in COVALENT-211, COVALENT-212 trials
Biomea Fusion (BMEA) announced that the first patient has been dosed in its newly initiated Phase II programs, COVALENT-211 and COVALENT-212, evaluating icovamenib in patients with type 2 diabetes, ma...
Biomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care Therapies
COVALENT-211 Phase II enrolling insulin-deficient type 2 diabetes patients COVALENT-212 Phase II enrolling type 2 diabetes patients uncontrolled with a GLP-1 receptor agonist-based therapy Topline 26...
Biomea Fusion Transcript: Fireside chat
Icovamenib, a novel menin inhibitor, shows promise in restoring beta cell function and reducing A1C in diabetes patients, especially those failing GLP-1 therapies. Ongoing trials aim for key data by year-end, with the potential to delay insulin dependence and reshape diabetes treatment.
Biomea Fusion Transcript: Fireside chat
The discussion highlighted imminent phase I data for BMF-650, designed for improved oral bioavailability and tolerability in obesity, and icovamenib's novel approach to restoring beta cell function in diabetes. Key clinical milestones are expected in Q2 and Q4, with a cash runway into 2027.
Citi ups Biomea Fusion target, adds ‘upside 90-day catalyst watch’
Citi raised the firm’s price target on Biomea Fusion (BMEA) to $7 from $6 and keeps a Buy rating on the shares. Citi also added an “upside 90-day catalyst watch”…
Biomea Fusion Reports Full Year 2025 Financial Results and Corporate Highlights
SAN CARLOS, Calif., March 24, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today reported ...
Biomea Fusion presents Phase II Covalent-111 data in Type 2 Diabetes
Biomea Fusion (BMEA) announced that Juan Pablo Frias, MD, delivered an oral presentation at the 19th International Conference on Advanced Technologies & Treatments for Diabetes in Barcelona on March 1...
Biomea Fusion Presents Phase II COVALENT-111 Data in Type 2 Diabetes at the 19th International Conference on Advanced Technologies & Treatments for Diabetes 2026
SAN CARLOS, Calif., March 14, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea,” “Biomea Fusion,” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced ...
Biomea Fusion Transcript: The Citizens Life Sciences Conference 2026
The company is advancing two in-house assets for diabetes and obesity, including a novel menin inhibitor with durable effects and an oral GLP-1 agent designed for better adherence. Key clinical data readouts are expected in 2024, with phase III planning underway.
Biomea Fusion management to meet virtually with Craig-Hallum
Virtual Meeting to be held on March 16 hosted by Craig-Hallum.
Biomea Fusion Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
Two oral candidates are advancing: Icovamenib for insulin-deficient and GLP-1-failing diabetes patients, and BMF-650 for weight loss. Icovamenib shows durable A1C reduction post-treatment, with phase II trials underway and key data expected by year-end and Q4 2026.
Biomea Fusion Transcript: 44th Annual J.P. Morgan Healthcare Conference
The company is advancing two main assets for diabetes and obesity, with icovamenib showing durable A1C reductions and BMF-650 progressing in early clinical trials. Two phase II studies are set to enroll in Q1, with key data expected in Q4, and the cash runway extends into early 2027.
Biomea Fusion initiated with a Buy at Rodman & Renshaw
Rodman & Renshaw initiated coverage of Biomea Fusion (BMEA) with a Buy rating and $8 price target